Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study

Journal of the American College of Cardiology

Volumn 44, Issue 10, 2004, Pages 1996-2002

  Walter, Mary F ^a   Jacob, Robert F ^a   Jeffers, Barrett ^c   Ghadanfar, Mathieu M ^c   Preston, Gregory M ^d   Buch, Jan ^c   Mason, R Preston ^a,b,e  

^a ELUCIDA RESEARCH LLC   (United States)

^b Brigham Women's Hosp   (United States)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e Beverly Massachusetts 01915 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NITRATE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MALE; OXIDATION; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SPECTROPHOTOMETRY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 8144219523     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.08.029     Document Type: Article

References (45)

1. J.L. Witztum, J.A. Berliner Oxidized phospholipids and isoprostanes in atherosclerosis Curr Opin Lipidol 9 1998 441 448
2. G.M. Chisolm, D. Steinberg The oxidative modification hypothesis of atherogenesis: an overview Free Radical Biol Med 28 2000 1815 1826
3. D. Steinberg Low density lipoprotein oxidation and its pathobiological significance J Biol Chem 272 1997 20963 20966
4. K.J. Sanderson, A.M. van Rij, C.R Wade Lipid peroxidation of circulating low density lipoproteins with age, smoking and in peripheral vascular disease Atherosclerosis 118 1995 45 51
5. A.B. Bridges, N.A. Scott, G.J Parry Age, sex, cigarette smoking and indices of free radical activity in healthy humans Eur J Med 2 1993 205 208
6. L. Ghiadoni, A. Magagna, D Versari Different effect of antihypertensive drugs on conduit artery endothelial function Hypertension 41 2003 1 6
7. J. Zahavi, J.D. Betteridge, N.A Jones Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia Am J Med 70 1981 59 64
8. A.S. Yalcin, N. Sabuncu, A Kilinc Increased plasma and erythrocyte lipid peroxidation in hyperlipidemic individuals Atherosclerosis 80 1989 169 170
9. S. Nacitarhan, T. Ozben, N. Tuncer Serum and urine malondialdehyde levels in NIDDM patients with and without hyperlipidemia Free Radical Biol Med 19 1995 893 896
10. G. Noberasco, P. Odetti, D Boeri Malondialdehyde (MDA) level in diabetic subjects: relationship with blood glucose and glycosylated hemoglobin Biomed Pharmacother 45 1991 193 196
11. B. Pitt, R.P. Byington, C.D Furberg Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events Circulation 102 2000 1503 1510
12. R.P. Mason, P. Marche, T.H. Hintze Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine Arterioscler Thromb Vasc Biol 23 2003 2155 2163
13. J. Templar, S.P. Kon, T.P. Milligan, D.J. Newman, M.J. Raftery Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method Nephrol Dial Transplant 14 1999 946 951
14. X.Y. Li, C.K. Chow An improved method for the measurement of malondialdehyde in biological samples Lipids 29 1994 73 75
15. G.B. Mancini, S.B. Simon, M.J. McGillem, M.T. LeFree, H.Z. Friedman, R.A. Vogel Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method Circulation 75 1987 452 460
16. The NHLaBICAS Study Investigators A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease and a registry of consecutive patients undergoing coronary angiography Circulation 63 Suppl I 1981 I1 81
17. R.P. Byington, M.E. Miller, D Herrington Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Am J Cardiol 80 1997 1087 1090
18. M.A. Carbonneau, E. Peuchant, D. Sess, P. Canioni, M. Clerc Free and bound malondialdehyde measured as thiobarbituric acid adduct by HPLC Clin Chem 37 1991 1423 1429
19. E.A. Meagher, G.A. Fitzgerald Indices of lipid peroxidation in vivo: strengths and limitations Free Radical Biol Med 28 2000 1745 1750
20. V. Cavalca, G. Cighetti, F Bamonti Oxidative stress and homocysteine in coronary artery disease Clin Chem 47 2001 887 892
21. N. Sakuma, T. Hibino, T Sato Levels of thiobarbituric acid-reactive substance in plasma from coronary artery disease patients Clin Biochem 30 1997 505 507
22. H.C. Chiu, J.R. Jeng, S.M. Shieh Increased oxidizability of plasma low-density lipoprotein from patients with coronary artery disease Biochim Biophys Acta 1225 1994 200 208
23. S. Ehara, M. Ueda, T Naruko Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes Circulation 103 2001 1955
24. T. Weinbrenner, M. Cladellas, M.I Covas High oxidative stress in patients with stable coronary heart disease Atherosclerosis 168 2003 99 9106
25. W.F. Penny, O. Ben-Yehuda, K Kuroe Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein J Am Coll Cardiol 38 2001 2136 2137
26. R. Kranzhofer, J. Schmidt, C.A.H Pfeiffer Angiotensin induces inflammatory activation of human vascular smooth muscle cells Arterioscler Thromb Vasc Biol 19 1999 1623 1629
27. S.D. Cushing, J.A. Berliner, A.J Valentine Minimally modified LDL induces monocyte chemotactic protein 1 in human endothelial and smooth muscle cells Proc Natl Acad Sci USA 87 1990 5134 5138
28. H.J. Moshage, H.M. Roelofs, J.F van Pelt The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes Biochem Biophys Res Commun 155 1988 112 117
29. P.M. Ridker, N. Rifai, L Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
30. L. Vergani, S. Hatrik, F Ricci Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability Circulation 101 2000 1261 1266
31. G.M. Rubanyi, P.M. Vanhoutte Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor Am J Physiol 250 1986 H822 7
32. S.L. Hazen, J.P. Gaut, J.R Crowley Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions Biochemistry 352 2000 693 699
33. J. Hulthe, B. Fagerberg Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (ARI study) Arterioscler Thromb Vasc Biol 22 2002 1162 1167
34. D. Pratico F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidatoin in vivo Atherosclerosis 147 1999 1 10
35. M.H. Shishehbor, M.L. Brenna, R.J Aviles Statins promote potent systemic antioxidant effects through specific inflammatory pathways Circulation 108 2003 426 431
36. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions Arterioscler Thromb Vasc Biol 17 1997 2975 2981
37. C. Vassalle, N. Botto, M.G Andreassi Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease Coronary Artery Dis 14 2003 213 218
38. W. Palinski, M.E. Rosenfeld, S Yla-Herttuala Low density lipoprotein undergoes oxidative modification in vivo Proc Natl Acad Sci USA 86 1989 1372 1376
39. J.T. Salonen, S. Yla-Herttuala, R Yamamoto Autoantibody against oxidised LDL and progression of carotid atherosclerosis Lancet 339 1992 883 887
40. I. Jialal, S. Devaraj Antioxidants and atherosclerosis: don't throw out the baby with the bath water Circulation 107 2003 926 928
41. D. Steinberg, J.L. Witztum Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trails conducted to date refute the hypothesis? Circulation 105 2002 2107 2111
42. J.W. Heinecke Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis Am J Cardiol 91 2003 12A-6A
43. F. Micheletta, S. Natoli, M Misuraca Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress in plasma but not in plaque Arterioscler Thromb Vasc Biol 24 2004 136 140
44. T.N. Tulenko, M. Chen, P.E. Mason, R.P. Mason Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis J Lipid Res 39 1998 947 956
45. 2+ channel blockers to the membrane lipid bilayer Mol Pharmacol 41 1992 315 321